Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling

Journal of Experimental Medicine

Volumn 185, Issue 9, 1997, Pages 1573-1584

  Cope, Andrew P ^a   Liblau, Roland S ^a   Yang, Xiao Dong ^a,d   Congia, Mauro ^a   Laudanna, Carlo ^a   Schreiber, Robert D ^b   Probert, Lesley ^c   Kollias, George ^c   McDevitt, Hugh O ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HELLENIC PASTEUR INSTITUTE   (Greece)

^d CELL GENESYS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; CELL FUNCTION; CELL SURVIVAL; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TARGET CELL;

ANIMALS; CALCIUM; CD4-POSITIVE T-LYMPHOCYTES; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-4; LYMPH NODES; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TH1 CELLS; TH2 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030911341     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.185.9.1573     Document Type: Article

References (38)

1. Vassalli, P. 1992. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 10:411-452.
2. Feldmann, M., F.M. Brennan, and R.N. Maini. 1996. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14: 397-440.
3. Saklatvala, J. 1986. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature (Lond.). 322:547-549.
4. Campbell, I.L., A. Iscaro, and L.C. Harrison. 1988. IFNγ and tumor necrosis factor-α cytotoxicity to murine islets of Langerhans. J. Immunol. 141:2325-2329.
5. Selmaj, K., and C.S. Raine. 1988. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann. Neurol. 23:339-346.
6. Williams, R.O., M. Feldmann, and R.N. Maini. 1992. Antitumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA. 89:9784-9788.
7. Ruddle, N.H., C.M. Bergman, K.M. McGrath, E.G. Lingenheld, M.L. Grunnet, S.J. Padula, and R.B. Clark. 1990. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 172:1193-2000.
8. Dick, A.D., P.G. McMenamin, H. Korner, B.J. Scallon, J. Ghrayeb, J.V. Forrester, and J.D. Sedgwick. 1996. Inhibition of tumour necrosis factor activity minimises target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina. Eur. J. Immunol. 26:1018-1025.
9. Elliott, M.J., R.N. Maini, M. Feldmann, F.M. Brennan, J.R. Kalden, C. Aontoni, J.S. Smolen, B. Leeb, F.C. Breedveld, J.D. Macfarlane et al. 1994. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105-1110.
10. van Dulleman, H.M., S.J. van Deventer, D.W. Hommes, H.A. Bijl, J. Jansen, G.N. Tytgat, and J. Woody. 1995. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 109: 129-135.
11. Jacob, C.O., and H.O. McDevitt. 1988. Tumor necrosis factor-α in murine autoimmune "lupus" nephritis. Nature (Lond.). 331:356-357.
12. Gordon, C., G.E. Ranges, J.S. Greenspan, and D. Wofsy. 1989. Chronic therapy with recombinant tumor necrosis factor-α in autoimmune NZB/W F1 mice. Clin. Immunol. Immunopathol. 52:421-434.
13. Jacob, C.O., S. Aiso, S.A. Michie, H.O. McDevitt and H. Acha-Orbea. 1990. Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-α and interleukin 1. Proc. Natl. Acad. Sci. USA. 87:968-972.
14. Yang, X.-D., R. Tisch, S.M. Singer, Z.A. Cao, R.S. Liblau, R.D. Schreiber, and H.O. McDevitt. 1994. Effect of tumor necrosis factor α on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J. Exp. Med. 180:99-1004.
15. Grewal, I.S., K.D. Grewal, F.S. Wong, D.E. Picarella, C.A. Janeway, Jr., and R.A. Flavell. 1996. Local expression of transgene encoded TNF-α in islets prevents autoimmune diabetes in NOD mice by preventing the development of autoreactive islet specific T cells. J. Exp. Med. 184:1963-1974.
16. Scott, B., R. Liblau, S. Degermann, L.A. Marconi, L. Ogata, A.J. Caton, H.O. McDevitt, and D. Lo. 1994. A role for non-MHC genetic polymorphism in susceptibility to spontaneous autoimmunity. Immunity. 1:73-82.
17. Keffer J., L. Probert, H. Cazlaris, S. Georgopoulos, E. Kaslaris, D. Kioussis, and G. Kollias. 1991. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO (Eur. Mol. Biol. Organ.) J. 10:4025-4031.
18. Liblau, R.S., R. Tisch, K. Shokat, X.-D. Yang, N. Dumont, C.C. Goodnow, and H.O. McDevitt. 1996. Intravenous injections of soluble antigen induces thymic and peripheral T-cell apoptosis. Proc. Natl. Acad. Sci. USA. 93:3031-3036.
19. Sheehan, K.C.F., N.H. Ruddle, and R.D. Schreiber. 1989. Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. J. Immunol. 142:3884-3893.
20. Rabinovich, P.S., C.H. June, A. Grossman, and J.A. Ledbetter. 1986. Heterogeneity among T cells in intracellular free calcium responses after mitogen stimulation with PHA or anti-CD3; simultaneous use of Indo-1 and immunofluorescence with flow cytometry. J. Immunol. 137:952-961.
21. Tartaglia, L.A., R.F. Weber, I.S. Figan, and D.V. Goeddel. 1991. Two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc. Natl. Acad. Sci. USA. 88: 9292-9296.
22. Scheurich, P., D. Thoma, U. Ucer, and K. Pfizenmaier. 1987. Immunoregulatory activity of recombinant tumor necrosis factor (TNF)-α: induction of TNF receptors on T cells and TNF-α-mediated enhancement of T cell responses. J. Immunol. 138:1786-1790.
23. Güler, M.L., J.D. Gorham, C. Hsieh, A.J. Mackey, R.G. Steen, W.F. Dietrich, and K.M. Murphy. 1996. Genetic susceptibilty to Leishmania: IL-12 responsiveness in TH1 cell development. Science (Wash. DC). 271:984-987.
24. Hart, P.H., G.F. Vitti, D.R. Burgess, G.A. Whitty, D.S. Piccoli, and J.A. Hamilton. 1989. Potential anti-inflammatory effects of interleukin-4: suppression of human monocyte tumor necrosis factor, interleukin-1 β and prostaglandin E2. Proc. Natl. Acad. Sci. USA. 86:3803-3807.
25. de Waal Malefyt, R., J. Abrams, B. Bennet, and J.E. de Vries. 1991. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174:1209-1220.
26. Ishida, H., T. Muchamvel, S. Sakaguchi, S. Andrade, S. Menon, and M. Howard. 1994. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J. Exp. Med. 179:305-310.
27. Zhou, T., C.K. Edwards III, P. Yang, Z. Wang, H. Bluethmann, and J.D. Mountz. 1996. Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor I. J. Immunol. 156:2661-2665.
28. Pennline, K.J., E. Roque-Gaffney, and M. Monahan. 1994. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin. Immunol. Immunopathol. 71:169-175.
29. Wogensen, L., X. Huang, and N. Sarvetnick. 1993. Leukocyte extravasation into the pancreatic tissue in transgenic mice expressing interleukin-10 in the islets of Langerhans. J. Exp. Med. 178:175-185.
30. Lee, M.-S., R. Mueller, L.S. Wicker, L.B. Peterson, and N. Sarvetnick. 1996. IL-10 is necessary and sufficient for autoimmune diabetes in conjunction with NOD MHC homozygosity. J. Exp. Med. 183:2663-2668.
31. Jacob, C.O., S. Aiso, R.D. Schreiber, and H.O. McDevitt. 1992. Monoclonal anti-tumor necrosis factor antibody renders non-obese diabetic mice hypersensitive to irradiation and enhances insulitis development. Int. Immunol. 4(5):611-614.
32. Cope, A.P., M. Londei, N.R. Chu, S.A.B. Cohen, F.M. Brennan, R.N. Maini, and M. Feldmann. 1994. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis J. Clin. Invest. 94:749-760.
33. Sallusto, F., and A. Lancavecchia. 1994. Efficient presentation of soluble antigen by cultured dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179:1109-1118.
34. Schwartz, R.H. 1996. Models of T cell anergy: is there a common molecular mechanism? J. Exp. Med. 184:1-8.
35. Sloane-Lancaster, J., T.H. Steinberg, and P.H. Allen. 1996. Selective activation of the calcium signaling pathway by altered peptide ligands. J. Exp. Med. 184:1525-1530.
36. Mueller, D L., M.K. Jenkins, L. Chiodetti, and R.H. Schwartz. 1990. An intracellular calcium increase and protein kinase C activation fail to initiate T cell proliferation in the absence of a costimulatory signal. J. Immunol. 144:3701-3709.
37. + T cells. J. Exp. Med. 184:19-29.
38. Hotamisligil, G.S., P. Peraldi, A. Budavari, R. Ellis, M.F. White, and B.M. Spiegelman. 1996. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α-and obesity-induced insulin resistance. Science (Wash. DC). 271:665-668.